|
||||||||||||||||||||||
![]() |
|
|
|
![]() |
Phase II/III cis-Platinum in 2-Drug and 3-Drug Combinations with VP-16 and DAVA for Advanced non-Oat Cell Carcinoma of the Lung
Basic Trial Information
Objectives I. Determine the efficacy of three combinations of chemotherapy in patients with extensive non-oat cell lung cancer. The combinations are VP-16/vindesine/cis-platinum, VP-16/cis-platinum, and vindesine/cis-platinum. II. Determine the qualitative and quantitative toxicities of these three chemotherapy combinations. III. Study and compare the response rates and duration of survival in patients with extensive non-oat cell lung cancer treated by these three chemotherapy combinations. Entry Criteria Disease Characteristics: See General Eligibility Criteria Patient Characteristics: See General Eligibility Criteria General Eligibility Criteria: Patients with measurable, histologically proven, metastatic non-oat cell carcinoma, who have received no prior chemotherapy, and no radiotherapy or surgery unless there is evidence of subsequent disease progression. Patients must have a life expectancy of at least 12 weeks and have adequate hematologic, hepatic, and renal function. Expected Enrollment 100 patients (approximately 33 per treatment arm) will be entered over 12-18 months. Protocol closed February 1983. Outline Randomized study. Arm I: 3-Drug Combination Chemotherapy. cis-Platinum, CACP, NSC-119875; Vindesine, DAVA, NSC-245467; VP-16213, VP-16, NSC-141540. Arm II: 2-Drug Combination Chemotherapy. CACP; VP-16. Arm III: 2-Drug Combination Chemotherapy. CACP; DAVA. Trial Lead Organizations M. D. Anderson Cancer Center at University of Texas
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. |
![]() |
![]() |
![]() |
![]() |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
![]() A Service of the National Cancer Institute |
![]() |
![]() |